Adult reading a plain health booklet beside a glass of water at a bright home table.

FDA-Approved Alcohol Use Disorder Medications | NM

Three FDA-approved alcohol use disorder medications can support treatment: acamprosate, disulfiram, and naltrexone. Their purposes and medical limits differ. Medication can work alongside outpatient alcohol recovery care and individual and group counseling, but choosing a prescription requires an assessment of your health, alcohol use, and treatment goals.

Learning that medication is an option can bring relief, uncertainty, or both. You may want help maintaining abstinence, reducing heavy drinking, or understanding why previous efforts were difficult. Those concerns deserve a respectful medical discussion, without assuming that one medicine fits everyone. The National Institute on Alcohol Abuse and Alcoholism (NIAAA) describes medication, behavioral treatment, and mutual-support groups as distinct options that can contribute to care. Understanding their different roles helps separate an ongoing treatment decision from other needs, including alcohol withdrawal evaluation and care for accompanying health conditions.

Written by Tim Francis, SUD Content Specialist. Tim is a nonclinical author. This guide supports discussion with qualified professionals.

Which alcohol use disorder medications are FDA approved?

Acamprosate, disulfiram, and naltrexone are the three FDA-approved medications for alcohol use disorder, or AUD. Each has a different treatment role. They can complement ongoing alcohol recovery care; the existing explanation of naltrexone and alcohol cravings addresses that medication's craving-related role in more detail.

NIAAA identifies all three medicines as treatment options that can help people stop or reduce drinking and prevent a return to drinking. Approval applies to a particular medical use. It does not mean that the medicines work identically, suit every person, or remove the need for follow-up. A prescription is one part of a treatment plan shaped around the person's needs.

  • Acamprosate: Supports abstinence and can help with symptoms experienced after stopping alcohol.
  • Disulfiram: Produces an unpleasant alcohol reaction that can support a goal of not drinking.
  • Naltrexone: Can reduce alcohol cravings and alcohol consumption; oral and injectable forms are used for AUD.

The word “medication” can suggest that treatment must focus entirely on biology. In practice, medication and behavioral care address connected needs. A medicine may reduce a barrier to change, while counseling helps with habits, stress, relationships, and situations associated with drinking. SAMHSA describes medications and behavioral therapies as complementary parts of substance use disorder treatment, with medication decisions tailored to each patient.

These medicines are also nonaddictive, according to NIAAA. Using prescribed AUD medication is a medical treatment decision, not evidence that someone has failed at recovery. At the same time, “nonaddictive” does not mean free of side effects or precautions. The useful distinction is between a medicine's potential treatment benefit and the separate assessment of its suitability for a particular person.

How do alcohol use disorder medications differ in purpose and limits?

AUD medications differ in what they are intended to help change: maintaining abstinence, discouraging drinking through an alcohol reaction, or reducing alcohol's appeal and consumption. Alcohol recovery treatment and individual and group therapy provide context for those goals, but these differences do not create a universal medication ranking.

The comparison below describes purpose and limits, rather than a way to select a prescription yourself. It draws on NIAAA's treatment overview and SAMHSA's information about acamprosate, disulfiram, and naltrexone.

FDA-approved AUD medications: treatment purposes and important limits
MedicationMain treatment purposeImportant limitExamples of medical considerations
AcamprosateSupports abstinence by helping with alcohol-related changes that can persist after stopping drinking.Its ongoing recovery role is different from managing acute alcohol withdrawal.Severe kidney disease prevents its use. Pregnancy and breastfeeding require individualized medical consideration.
DisulfiramSupports a no-drinking goal through an unpleasant reaction if alcohol is consumed.Does not reduce alcohol cravings or treat alcohol withdrawal.Severe heart disease, severe liver disease, psychosis, and exposure to alcohol-containing products are important concerns.
NaltrexoneCan reduce alcohol cravings and consumption by blocking effects involved in alcohol's rewarding experience.Its opioid-blocking action creates separate precautions involving opioid use and opioid-containing medicines.Opioid dependence, liver problems, other medical conditions, and current medicines affect assessment.

For acamprosate, SAMHSA describes a possible restoration of neurotransmitter balance disrupted by chronic alcohol use. That explanation should not be treated as a complete account of how every person will respond. The practical treatment role is support during recovery, especially around abstinence. It is different from disulfiram's alcohol-reaction mechanism.

Disulfiram interferes with alcohol breakdown. Drinking while it is active can cause symptoms such as flushing, nausea, vomiting, and palpitations. Its benefit does not come from removing the desire to drink. Naltrexone has a different action and does not use disulfiram's aversive alcohol reaction. These distinctions explain why substituting one medicine for another is a medical decision, not a simple exchange between equivalent products.

What can AUD medications do for abstinence and reduced drinking?

AUD medication can support abstinence, reduced drinking, or prevention of a return to drinking, depending on the medicine and treatment plan. A reduction in alcohol cravings is one possible effect, while outpatient recovery support addresses the broader work of changing alcohol use and daily functioning.

Abstinence means not drinking alcohol. Reduced drinking means a decrease in drinking, but it does not automatically establish that remaining alcohol use is medically appropriate. NIAAA explains that abstinence may be necessary for sustained recovery for some people, depending on AUD severity, health, and individual circumstances. A population-level finding that treatment can reduce drinking cannot determine a suitable drinking goal for one reader.

The medications also support these goals differently. Acamprosate has an established role in helping maintain abstinence. Disulfiram supports a no-drinking goal because alcohol exposure causes an unpleasant reaction. Naltrexone can help reduce alcohol consumption. This does not make disulfiram an appropriate way to attempt controlled drinking, or establish that another medicine makes drinking harmless.

Craving is only one treatment target. A person can experience less desire to drink and still face stressful relationships, familiar drinking routines, or situations associated with past use. Conversely, having cravings does not mean that all treatment benefit has disappeared. NIDA describes treatment as addressing substance use, symptoms, consequences, and functioning. Those are related outcomes, but they are not interchangeable.

It can help to distinguish a treatment goal from a guaranteed result. A medicine may support a goal without producing the same response for everyone. Progress may include changes in alcohol use alongside improvements in health, relationships, and responsibilities. The plan remains open to adjustment rather than becoming a test of willpower or a promise that medication will remove every difficulty.

Why don't AUD medications replace alcohol withdrawal care?

Alcohol withdrawal care addresses the physical and emotional effects that can occur when alcohol use stops or decreases. Continuing outpatient alcohol recovery and addiction counseling address longer-term needs. An ongoing AUD prescription does not establish that stopping alcohol without medical supervision is appropriate for a particular person.

NIAAA warns that suddenly stopping after prolonged heavy drinking can cause potentially life-threatening withdrawal. Symptoms can include nausea, rapid heart rate, and seizures. Medical evaluation helps determine the care needed during this transition. The question is different from deciding which medication might support recovery after the immediate withdrawal needs have been addressed.

The three medicines in this comparison should therefore not be understood as interchangeable withdrawal treatments. SAMHSA specifically states that disulfiram does not treat withdrawal. Its acamprosate information describes use after most withdrawal symptoms have resolved, while its naltrexone information also distinguishes ongoing AUD treatment from the alcohol detoxification process. These descriptions are not instructions for starting a medicine or managing withdrawal at home.

The distinction works in both directions. Managing withdrawal can address an immediate medical need without resolving the full substance use disorder. Ongoing care may still need to address craving, alcohol-related behaviors, mental health, and social difficulties. NIDA describes both withdrawal-related treatment and continuing behavioral and medication treatment within the wider range of substance use care.

What health factors affect the suitability of AUD medications?

Medication suitability depends on more than the drinking goal. Kidney and liver health, other illnesses, pregnancy, and current medicines can affect the decision. Alcohol recovery care and counseling support can accompany treatment, while the prescribing assessment addresses these medical factors and each medication's particular precautions.

Kidney health matters for acamprosate. SAMHSA states that people with severe kidney disease should not start acamprosate. Pregnancy, plans for pregnancy, and breastfeeding also require medical consideration. These boundaries show why a medicine described as well tolerated can still be unsuitable in a particular health situation. General descriptions of benefit cannot replace the medical assessment.

Disulfiram has distinct health and exposure concerns. SAMHSA identifies severe heart disease or heart failure, severe liver disease, and psychosis as reasons not to take it. Seizure history and other conditions also affect assessment. Alcohol in some medicines, mouthwash, foods, and other products can cause a reaction. Alcohol reactions can remain possible after disulfiram has been stopped, so discontinuation does not immediately remove that concern.

Naltrexone requires attention to opioid exposure. Its opioid-blocking action matters even when the treatment goal concerns alcohol. SAMHSA describes precautions involving current opioid use, physical opioid dependence, opioid withdrawal, and opioid-containing medicines. Liver problems and other health conditions also require assessment. This is one reason that a complete medication review matters; a medicine used for another purpose can affect an AUD treatment decision.

Side effects are another part of the benefit-and-risk discussion. Examples include diarrhea with acamprosate, a metallic or garlic-like taste with disulfiram, and nausea with naltrexone. These examples are not complete lists. New, persistent, or bothersome symptoms deserve medical attention rather than being dismissed as an unavoidable part of recovery. Serious reactions require prompt evaluation.

These factors should not be turned into a self-selection chart. Having a condition does not identify an alternative medicine automatically, and lacking a listed concern does not establish suitability. A prescriber considers the full picture, including medicines, supplements, health history, alcohol use, and treatment goals. The same information can also guide appropriate monitoring during care.

How do AUD medications complement counseling and recovery support?

AUD medications and behavioral care can address different parts of the same condition. Medication may reduce a biological barrier, while individual and group addiction counseling supports behavior change. Peer support alongside clinical care offers a different kind of connection; it does not perform the same job as prescribing or therapy.

NIAAA describes behavioral treatment as work that can build coping skills, social support, reachable goals, and ways to respond to triggers. A medication cannot conduct that work for someone. Counseling can help connect treatment goals with specific situations, such as stress after work or a relationship pattern associated with drinking, without assuming those examples apply to every person.

  • Medication treatment: Addresses medication-specific targets and requires prescribing assessment and monitoring.
  • Behavioral treatment: Helps change alcohol-related thoughts and behaviors and develop coping skills.
  • Mutual-support groups: Provide peer-led fellowship and recovery support outside professional treatment.
  • Peer support: Adds lived-experience understanding and practical connection without replacing clinical care.

NIDA distinguishes mutual-help groups from professionally delivered treatment. A group can provide useful support without diagnosing a condition or managing a prescription. Likewise, attending counseling does not require someone to prove that medication is unnecessary. These supports can coexist because they address different needs rather than competing for a single definition of recovery.

Respect and collaboration also matter. Disulfiram's alcohol-reaction mechanism should not turn treatment into punishment. NIAAA emphasizes empathy, motivational support, and behavior change rather than heavy confrontation. For loved ones, supporting recovery does not mean taking responsibility for another adult's illness. Family members may need support of their own while remaining respectful of the person's decisions.

Choice Recovery Path's Intensive Outpatient Program (IOP) in Albuquerque, NM describes weekly group and individual therapy, substance use education, and recovery tools. Those verified services provide a complementary recovery-care context. The program description does not establish that any particular AUD medication is available or suitable for an individual.

How can ongoing care assess progress with AUD medications?

Ongoing care assesses medication benefit, side effects, alcohol use, and daily functioning over time. It can also examine how recovery support fits changing needs. Choice's IOP description explains its therapy framework, while Choice's contact information provides a route to discuss current outpatient options, separate from an individual prescribing decision.

NIAAA describes AUD recovery as an ongoing process that can involve continued follow-up and treatment adjustment. Progress is therefore broader than a single good day or difficult week. A medication's effect needs to be considered alongside its tolerability and the person's goals, without assuming that every change in mood or drinking has one cause.

Several areas can contribute to that assessment:

  • Changes in drinking and return-to-drinking patterns.
  • Cravings and situations linked with alcohol use.
  • Medication side effects and new health concerns.
  • Participation in treatment and recovery support.
  • Health, relationships, responsibilities, and quality of life.

A return to drinking does not, by itself, prove that treatment has failed. NIDA explains that a return to substance use signals a need to consider resuming or modifying treatment. That can involve reassessing the medication plan, behavioral support, or other needs. It does not justify changing a prescription independently or assuming that the same response fits every medication.

The meaning of progress also depends on the treatment goal. Maintaining abstinence, reducing heavy drinking, and improving daily functioning are different measures. Improvement in one area deserves recognition, but it may not resolve another medical concern. A person can benefit from counseling while still needing a medication adjustment, or tolerate a medicine while needing more support for alcohol-related behavior.

Recovery does not need to be framed as a contest between medication and personal effort. Medical treatment, skills, relationships, and persistence can all have a place. Follow-up allows the plan to respond to real changes rather than holding someone to an approach that no longer meets their needs.

FAQ

Are FDA-approved alcohol use disorder medications addictive?

NIAAA describes the three approved AUD medications as nonaddictive. Taking one as prescribed is treatment for a medical condition, not evidence of replacing alcohol addiction with another addiction. Nonaddictive does not mean suitable for everyone or free of side effects. Each medicine still requires assessment, appropriate prescribing, and attention to its specific precautions.

Can medication cure alcohol use disorder?

AUD medications can support treatment, but they do not provide a cure. They may help people maintain abstinence, reduce drinking, or avoid a return to drinking. Ongoing care can also address coping, health, relationships, and daily functioning. The treatment plan may need adjustment over time as needs and circumstances change.

Do all alcohol use disorder medications reduce cravings?

No. The medications have different purposes. Naltrexone can reduce alcohol cravings, and acamprosate can support recovery after stopping alcohol. Disulfiram does not reduce cravings; it causes an unpleasant reaction when alcohol is consumed. Understanding those differences helps explain why the medicines are not interchangeable and why treatment decisions require an individual medical assessment.

Are alcohol withdrawal treatment and ongoing AUD medication treatment the same?

No. Withdrawal care addresses symptoms and medical risks that can occur when alcohol use stops or decreases. Ongoing AUD medication treatment supports longer-term changes in alcohol use. A prescription for continuing treatment does not establish that withdrawal can be managed without medical supervision. People who may be physically dependent on alcohol need medical guidance before a major change.

Can counseling and mutual-support groups serve different roles during medication treatment?

Yes. Professional counseling helps address alcohol-related behaviors, coping skills, motivation, and treatment goals. Mutual-support groups provide peer-led fellowship and recovery support rather than prescribing or clinical treatment. Both can contribute alongside medication, depending on the person's needs and preferences. Participation in one does not make the others unnecessary or require a single approach to recovery.

Sources

If complementary outpatient support in Albuquerque, NM, may be useful, you can review Choice Recovery Path's Intensive Outpatient Program (IOP) or contact Choice to discuss current options. You do not need to choose a medication before starting that conversation.

Accessibility tools

Choose the adjustments you need. Your choices are saved on this browser when storage is available.

Accessibility Statement